Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine currently in development may delay the worsening of liver cancer. The medicine is an oral signal transduction inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Medicines in Development for Cancer  
  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • There are 3 million more cancer survivors today than there were a decade ago.  
  • More than half of cancer deaths in the U.S. are due to preventable causes.  
  • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.